**职位招聘 - 默沙东研发(中国)有限公司资深科学家**

**Senior Research Scientist, Bioinformatics**

**Department: Strategic Planning and Research Informatics**

**Report to: Head of Strategic Planning and Research Informatics**

**Location: Beijing, China**

We are seeking a highly motivated and enthusiastic scientist in bioinformatics to join a high-performance team of informatics scientists and data science professionals to further the objectives and reputation of MSD, and to drive drug discovery and development, especially in immuno-oncology area in China and globally.

The successful candidate will lead/contribute to a broad scope of bioinformatics/health informatics projects-

* Develop computational pipeline and analytical tools to analyze, visualize and summarize NGS and other molecular data from clinical trials, preclinical data.
* Use molecular data to identify biomarkers and molecularly defined groups of patients most likely to benefit from individual therapies, with a focus on translating biomarker-driven strategies into the clinic.

**Qualifications**

**Required**

* A PhD (or with equivalent experience) with a focus on Bioinformatics, computational biology, or related fields.
* Strong technical expertise in developing and utilizing bioinformatics analytic tools.
* Hands-on analysis experience with large genetic/genomic datasets.
* A background in statistics, including familiarity with mathematics and statistics packages such as MatLab, or R, or SAS.
* Excellent oral and written communication skills in Chinese and English.
* Experience with a matrix environment and ability to effectively collaborate with colleagues from a wide range of disciplines.

**Preferred:**

* Understanding of the major concepts of immuno-oncology biology.
* Understanding of drug discovery and development processes.
* Record of publishing in high profile scientific journals.

Please send resume to: gefei.zeng@merck.com; WeChat ID: GefeiZeng

**关于默沙东**

默克（在美国与加拿大以外，默克被称为默沙东）是全球医疗行业的领先者,世界500强企业。在处方药、疫苗、与动物保健产品邻域，默沙东为全球140多个国家提供创新的产品。业务的核心邻域包括肿瘤，疫苗，糖尿病及抗感染。

公司总部位于美国新泽西州肯尼沃斯，全球共有员工约6.9万人，2017年销售收入为401亿美元，研发支出为73亿美元。

中国是默沙东全球增长战略中至关重要的一部分。默沙东中国总部设在上海，中国研发中心总部设在北京，工厂设在杭州，员工总数超过5000人，为中国各地的患者和其他客户提供创新的药品和服务。默沙东在中国提供涵盖肿瘤，心血管、抗感染、男性健康、女性健康、骨科、疼痛、皮肤、呼吸、糖尿病、专科药品、辅助生殖等领域的约50种人用药品和疫苗。同时还向中国市场提供46种动物保健产品，用以预防和治疗家禽家畜以及宠物的疾病。

**默沙东研发中心**于2011年在北京成立。目前，默沙东中国研发中心有800多名员工在此进行药物研发，定量分析，数据管理，转化性研究，临床开发，注册事务以及其他与外部合作的药品科研项目。

默沙东中国研发中心是默沙东实验室在中国的关键战略组成部分，是中国‘根植中国，造福中国，根植中国，服务全球’战略的重要体现。在过去的6年里，默沙东研发中心将20多个新产品或新适应症在中国注册，包括4价和9价宫颈癌疫苗，丙型肝炎药物择必达，及肿瘤免疫治疗药物可瑞达（Keytruda）等重磅创新产品。

自默沙东中国研发中心成立之日起，研发中心就非常注重与科研院校，科研机构的紧密合作，培养研究型，创新性人才，并于2013年4月获得国家博士后管理委员会批准成立默沙东中国研发中心博士后科研工作站。